PACB trade ideas
PACB - fill the gap and then move back up Based on idea below:
Should fill gap at 40 and proceed.
Exit at 60.
PACB - Strong uptrend about to resume?Last higher low coincides with 20 SMA - which I think can act as safer stop-loss
Up she goes - Genomics for the win.An ARKG favorite, this briefly touched the 9 EMA and is going back up on strong buying volume. Yesterday was a gift from the gods of an entry point and a long hold for those who are in it to win it in a game-changing technology in a huge growth sector.
$PACB Falling Wedge BreakoutCalled this out at $20.40 when wedge broke up, $PACB is a strong long term holding. Has run up massively this year but probably has more room to go, especially in the long term.
A note on the two trendines. I had alerts on both these trendines. Why? It's a messy but clear downward wedge on a high beta, small cap. The 'way' that PACB (and the entire genomics sector) moves is in leaps, not steps. I set two trendline alerts so I would know when to go absolutely long (2nd trendline), and where to check to see if I should go long (1st trendline).
PACB - Buy the dips (Anatomy of a multi-bagger)Recently there are many small stocks that broke out of a long term base spanning 2 years or more. How do we identify penny stocks with good odds of being a multi-bagger?
PACB is one such example with the right criteria that increased it's odds of having a trend that is sustainable to great extends.
Criteria:
1. long term base/bottoming formation (preferably 2 years or more)
2. breakup of a long term resistence with good volume (scroll out at least 2-5 years to see this resistence). This is when we first begin to stake.
3. retest of this breakup level several days or a couple of weeks later. Rejecting this level will affirm that the long term resistence has now turned support.
4. Began a strong uptrend with short term retracement that is usually not more than 38% of the last swing up. Pennants and flags are usually seen during those dips.
We can add to our positions (especially in the initial few dips) and raise our trailing stops to several ticks below the last dip. However this could mean we get stopped out prematurely at times and might need to re-establish positions if the chart looks right again.
Remember we are talking about odds here, not guarantees. :) Money management and position sizing is still needed to ensure we do not lose our pants should the trade not work out.
Good luck!
Disclaimer: This is just my own analysis and opinion for discussion and is not a trade advice. Kindly do your own due diligence and trade according to your own risk tolerance. Thank you. Feel free to give me your thoughts ! :)
massive breakout after multi-year base a multi-quarter monsterlarge volume large price increase and initial breakout price target 20-25% higher from current price. I own this stock after holding support at the 10day moving average. the fundamentals of genomic testing and widespread adoption is a significant trend driving change in the healthcare industry.
Pullback to the 50 SMA - nothing has changed. Healthy CorrectionA well-needed healthy pullback occurred and touched the 50SMA - should see money pouring back in for the January effect around the corner. An $ARKG favorite with a heavy weighting in their portfolio. Perfect opportunity for sideliners to have taken a position today. Good luck!
PACB - December 27, 2020Pacific Biosciences of California is a biotech company that develops and manufactures systems for gene sequencing and is currently the largest position in the ARK Genomic Revolution ETF which is the best performing ETF for ARK. The next big change to healthcare will be the ability to eliminate genetic diseases and prevent certain cancers due to the ability to genetically modify humans. Kathie Wood believes stocks related to the genetic analysis and genetic engineering industry have the potential to grow even faster than stocks related to the electric vehicle industry and clean energy industry in the next 5 years. The TAM is expected to increase 6.6x from 2019 to 2025. PACB recently proved through a Precision FDA Challenge that their equipment is more reliable with the fewest errors when compared to their competitors such as Illumina and ONT PEPPER. They have 81.67% institutional ownership showing strong confidence in the company’s future. PACB recently raised $93M of capital in August 2020.
PACB - retracement about to completeClear uptrend despite regular retracements up to 50%. Can it go another level up? Will wait and see.
$PACBBear pennant? possibly targeting $9.58 if it breaks to the downside looks like moving averages about to cross on 1hour (Death cross)
PACB:NASDAQ - PACIFIC BIOSCIENCES CALIFORNIA - Nice steady runPacific Biosciences provides an integrated platform for genetic analysis and its sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. Has had a nice steady run and seems to be able to stay within a tighter 12% trail. RSI is pretty high so if you are looking for an entry perhaps wait for a pullback. Worth a watch.
chart requestim not bullish here, so close to a big monthly resistance. just wait a couple more dollars if you arent in yet...see if it breaks or not! gl
PACB LongAdded today. Looking strong for next few months at least + 220 call options vs 0 put options..
Pacific Biosciences set to rally Pacific Biosciences of California, Inc. PACB reported fourth-quarter 2019 break-even earnings per share (EPS) versus the Zacks Consensus Estimate of a loss of 16 cents. The company had reported a loss of 21 cents in the year-ago quarter.
Revenues of this Zacks Rank #3 (Hold) company totaled $27.93 million, which outpaced the Zacks Consensus Estimate by 9.8%. Revenues improved 43% from the year-ago quarter’s tally.
FY19 at a Glance
Pacific Biosciences’ 2019 revenues totaled $77.7 million, up 17.2% but below the Zacks Consensus Estimate of $88.4 million.
Adjusted loss per share was 55 cents, narrower than the Zacks Consensus Estimate of a loss of 71 cents. The company had reported a loss of 76 cents in 2018.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $24.6. million, up 49.4% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.4 million, up 9.4% year over year.
PACB - Can we find a place to short this.Momentum is shifting down. We have multiple gaps to fill and very decent support. If we miss the short we can take longs at the red horizontal lines.
